Repligen Corporation (RGEN) is currently trading at $147.01 with a Wall Street consensus price target of $176.11, implying potential upside of 19.8% over the next 12 months. 19 analysts currently cover RGEN, with a consensus rating of Buy — 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $220.0, while the most cautious has a target of $142.0.
RGEN operates in the Healthcare sector with a market capitalisation of $8B. The stock is down 10.6% year-to-date and is currently trading near the upper end of its 52-week range of $100.99 – $175.77.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for RGEN, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →